SI4114465T1 - Režim odmerjanja anti-IFNAR1 za subkutano injiciranje - Google Patents

Režim odmerjanja anti-IFNAR1 za subkutano injiciranje

Info

Publication number
SI4114465T1
SI4114465T1 SI202230007T SI202230007T SI4114465T1 SI 4114465 T1 SI4114465 T1 SI 4114465T1 SI 202230007 T SI202230007 T SI 202230007T SI 202230007 T SI202230007 T SI 202230007T SI 4114465 T1 SI4114465 T1 SI 4114465T1
Authority
SI
Slovenia
Prior art keywords
ifnar1
subcutaneous injection
dosing regimen
regimen
dosing
Prior art date
Application number
SI202230007T
Other languages
English (en)
Slovenian (sl)
Inventor
Catharina Lindholm
Yen Lin Chia
Rajendra Tummala
Lorin Roskos
Joachim Almquist
Tomas Rouse
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4114465(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI4114465T1 publication Critical patent/SI4114465T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Devices For Medical Bathing And Washing (AREA)
SI202230007T 2021-04-23 2022-04-21 Režim odmerjanja anti-IFNAR1 za subkutano injiciranje SI4114465T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28
EP22724683.2A EP4114465B1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Publications (1)

Publication Number Publication Date
SI4114465T1 true SI4114465T1 (sl) 2023-11-30

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202230007T SI4114465T1 (sl) 2021-04-23 2022-04-21 Režim odmerjanja anti-IFNAR1 za subkutano injiciranje

Country Status (25)

Country Link
US (4) US20220340669A1 (https=)
EP (2) EP4114465B1 (https=)
JP (2) JP7484027B2 (https=)
KR (2) KR20230166134A (https=)
CN (2) CN120392997A (https=)
AU (2) AU2022260531B2 (https=)
BR (1) BR112023021761A2 (https=)
CA (1) CA3216387A1 (https=)
CL (1) CL2023003114A1 (https=)
CO (1) CO2023015498A2 (https=)
DK (1) DK4114465T5 (https=)
ES (1) ES2963757T3 (https=)
FI (1) FI4114465T3 (https=)
HR (1) HRP20231255T1 (https=)
HU (1) HUE063562T2 (https=)
IL (1) IL307748A (https=)
LT (1) LT4114465T (https=)
MX (1) MX2023012465A (https=)
PL (1) PL4114465T3 (https=)
PT (1) PT4114465T (https=)
RS (1) RS64821B1 (https=)
SI (1) SI4114465T1 (https=)
SM (1) SMT202300382T1 (https=)
TW (1) TW202317182A (https=)
WO (1) WO2022223714A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
JP2023549872A (ja) * 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
PT4192882T (pt) * 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
CA2651866C (en) 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
EP2077858A4 (en) 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
ES2542836T3 (es) 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
PT2219452E (pt) 2007-11-05 2016-01-26 Medimmune Llc Métodos de tratamento de esclerodermia
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
AU2013274389A1 (en) * 2012-06-13 2015-01-22 Astrazeneca Ab Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
CA2995222C (en) * 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP3713955A4 (en) * 2018-09-18 2022-03-09 I-Mab Biopharma (Hangzhou) Co., Ltd. ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
FI4114465T3 (fi) 2023-10-31
JP7484027B2 (ja) 2024-05-15
MX2023012465A (es) 2024-04-04
CA3216387A1 (en) 2022-10-27
EP4114465A1 (en) 2023-01-11
AU2022260531B2 (en) 2024-03-07
PT4114465T (pt) 2023-11-03
IL307748A (en) 2023-12-01
CL2023003114A1 (es) 2024-04-19
KR20230166134A (ko) 2023-12-06
LT4114465T (lt) 2023-11-10
AU2022260531A1 (en) 2023-11-30
JP7805393B2 (ja) 2026-01-23
JP2024102205A (ja) 2024-07-30
DK4114465T3 (da) 2023-10-30
TW202317182A (zh) 2023-05-01
EP4114465B1 (en) 2023-08-30
ES2963757T3 (es) 2024-04-01
EP4306541A3 (en) 2024-03-27
KR20250092298A (ko) 2025-06-23
SMT202300382T1 (it) 2024-01-10
EP4306541A2 (en) 2024-01-17
BR112023021761A2 (pt) 2023-12-26
CN120392997A (zh) 2025-08-01
US12060429B2 (en) 2024-08-13
HUE063562T2 (hu) 2024-01-28
WO2022223714A1 (en) 2022-10-27
DK4114465T5 (da) 2024-07-22
AU2024201743A1 (en) 2024-04-04
CN120514844A (zh) 2025-08-22
US20240360231A1 (en) 2024-10-31
HRP20231255T1 (hr) 2024-02-02
JP2024511227A (ja) 2024-03-12
AU2022260531A9 (en) 2023-12-07
US20220340669A1 (en) 2022-10-27
PL4114465T3 (pl) 2024-04-08
US20230365698A1 (en) 2023-11-16
US20240400699A1 (en) 2024-12-05
CO2023015498A2 (es) 2023-11-30
RS64821B1 (sr) 2023-12-29

Similar Documents

Publication Publication Date Title
SI4114465T1 (sl) Režim odmerjanja anti-IFNAR1 za subkutano injiciranje
PL3970769T3 (pl) Strzykawka bezigłowa
JP1704655S (ja) 医療用注入器
IL282972A (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
EP3247428C0 (en) ADDITIONAL DEVICE FOR ATTACHMENT TO AN INJECTION DEVICE TO DETERMINE DOSE OF DRUG USING OPTICAL SENSOR OF ARBITRARY INCREASE
JP1715469S (ja) 医療用注入器
EP4483926A4 (en) AUTOMATIC INJECTION PEN
PL3638373T3 (pl) Schematy dawkowania dla podawania ADC anty-CD19
ITUB20153137A1 (it) Terminale di ugello per iniettori di apparecchiature di stampaggio ad iniezione di materie plastiche
ITUB20152262A1 (it) Terminale di ugello per iniettori di apparecchiature di stampaggio ad iniezione di materie plastiche
PL4114638T3 (pl) Urządzenie do formowania wtryskowego
EP4410331A4 (en) SYRINGE
EP3912672C0 (en) NEEDLE-FREE IV INJECTION CONNECTION
FR3078541B1 (fr) Modele d’injection sous-cutanee ex vivo
EP3782676C0 (en) BALLOON TYPE LIQUID MEDICATION INJECTOR
EP4649975A4 (en) QUANTITATIVE INJECTION SYRINGE
EP3941372C0 (en) MEDICAL INSTRUMENT WITH INJECTION NEEDLES
EP4088764C0 (en) MEDICATION INJECTION DEVICE
EP4275717A4 (en) Injector
EP4408637A4 (en) INJECTION MOLDING OF COMPOSITE PARTS
ITUA20163291A1 (it) Dispositivo di iniezione per iniettare un additivo
EP4395852A4 (en) PRE-FILLED MANUAL INJECTION DEVICE
EP4029505C0 (en) INJECTION CONTAINING P-BORONOPHENYLALANINE
HUE051787T2 (hu) Injektor fröccsöntéshez
EP3590395C0 (en) INJECTOR NEEDLE